ODYY · Odyssey Health, Inc.

Odyssey Health, Inc. achieved a key milestone by closing the Master Technology and Sub-license Agreement with NeuRX Health, Inc. on April 21, 2026, following its initial execution on October 14, 2025. This deal grants Odyssey's wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide rights to market and distribute BreastCheck™, a non-invasive, at-home test for breast abnormalities that provides results in about 15 minutes via a mobile app by comparing breast temperatures. The product is positioned as a first-line screening tool to complement mammography, enhancing accessibility and potentially driving recurring revenue through frequent use. Regulatory registrations with the U.S. FDA, EU, and UK authorities enable broad commercialization, with sales anticipated in the second half of 2026. Amendment No. 1, effective the same day, refines payment terms: Odyssey must pay NeuRX 10% of net proceeds from its current equity line of credit until a Technology and Material Transfer Agreement is executed, increasing to 30% thereafter at Odyssey's discretion, after debt holder obligations. All customary closing conditions were met, solidifying the transaction. This positions Odyssey to enter the breast cancer screening market with a low-cost, differentiated product, supporting its shift toward revenue-generating assets and long-term growth.